Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 12/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16894129 | 0.87 | ALDH1A1 (0.51) | TRPA1ALDH1A1MEN1LMNAPOLB | |
| SCHEMBL16894077 | 0.85 | TRPA1 (0.53) | TRPA1ALDH1A1MEN1LMNAPOLB | |
| SCHEMBL16894092 | 0.85 | ALDH1A1 (0.59) | TRPA1ALDH1A1MEN1LMNAPOLB | |
| SCHEMBL16894084 | 0.85 | MMP1 (0.53) | TRPA1ALDH1A1MEN1LMNAPOLB | |
| SCHEMBL16894087 | 0.83 | ALDH1A1 (0.58) | TRPA1ALDH1A1MEN1LMNAPOLB | |
| SCHEMBL16894110 | 0.82 | TRPA1 (0.56) | TRPA1ALDH1A1MEN1LMNAPOLB | |
| SCHEMBL16894223 | 0.82 | TRPA1 (0.56) | TRPA1ALDH1A1MEN1LMNAPOLB | |
| SCHEMBL16894107 | 0.80 | TRPA1 (0.69) | TRPA1ALDH1A1MEN1LMNAPOLB | |
| SCHEMBL16894086 | 0.77 | ALDH1A1 (0.65) | TRPA1ALDH1A1MEN1LMNAPOLB | |
| SCHEMBL16894182 | 0.76 | TRPA1 (0.61) | TRPA1ALDH1A1MEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900642-B1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2018-02-28 | — | — | EP | disclosed |
| US-9580411-B2 | Substituted sulfonamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580411-B2 | Substituted sulfonamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150197509-A1 | SUBSTITUTED SULFONAMIDE SOLUTIONS | GENENTECH, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150197509-A1 | SUBSTITUTED SULFONAMIDE SOLUTIONS | GENENTECH, INC. (US) | 2015-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197509-A1 | SUBSTITUTED SULFONAMIDE SOLUTIONS | TRPA1, TRPV1, TRPV5 | TRPA1 1/4885ALDH1A1 949/4885MEN1 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.